Lilly’s Zepbound Outshines Novo’s Wegovy in First Head-to-Head Weight Loss Study
Efficacy Comparison:
In the SURMOUNT-5 study, patients taking Eli Lilly's Zepbound (tirzepatide) lost an average of 20.2% of their body weight, compared to 13.7% for those on Novo Nordisk's Wegovy (semaglutide)12.
Weight Loss Figures:
Over 72 weeks, Zepbound users lost 22.8 kg (50.3 lbs), while Wegovy users lost 15.0 kg (33.1 lbs)12.
Secondary Endpoint:
31.6% of Zepbound-treated patients achieved at least 25% weight loss, versus 16.1% in the Wegovy group1.
Market Impact:
The study's findings are expected to help Lilly gain ground in the obesity market, although analysts note that the data may only marginally boost Lilly's shares due to already high expectations13.
Competitive Landscape:
The study underscores tirzepatide's competitiveness against semaglutide, potentially providing Lilly with a superior advantage in labeling and sales13.
Sources:
1. https://www.biospace.com/drug-development/lilly-claims-key-weight-loss-victory-over-novo-in-head-to-head-study
2. https://www.bloomberg.com/news/articles/2024-12-04/lilly-s-zepbound-beats-novo-s-wegovy-in-first-head-to-head-trial
3. https://seekingalpha.com/article/4742128-lilly-head-to-head-data-lands-blow-on-novo-in-battle-for-weight-loss-supremacy